Aim: Pressure Ulcers are an important health care problem, recognized as ‘Never Events’ by the US Government. To date, there is no instrument to capture their health utility impact, or the value of treatments and prevention strategies. The Pressure Ulcer Quality of Life Utility Instrument...

Background: Trastuzumab has significantly improved survival outcomes for women with HER2 positive early breast cancer. Trastuzumab was established as a costeffective adjuvant treatment in 2006. We present an updated cost-effectiveness analysis from the UK perspective which explores assumptions...

The challenge of implementing high cost innovative technologies in health care systems operating under significant budgetary pressure has seen a radical shift in the health technology reimbursement landscape. New reimbursement strategies attempt to reduce the risk of making the wrong decision;...

Background - There are now a variety of preference based health related quality of life measures available. These instruments describe health in different terms and also use different methods for measuring individual preferences for health. Whilst these instruments have been shown to have...

The Expected Value of Information Framework has been proposed as a method for identifying when health care technologies should be reimbursed and when reimbursement should be withheld awaiting more evidence. The standard framework assesses the value of having additional evidence available to...

Harris has been a vocal critic of CEA and the QALY for over 20 years. In this paper we attempt to summarise and evaluate both Harris’ criticisms of CEA and the alternative procedures he commends to health care decision makers. Harris’ basic position is that all health benefits are...

Background: Patient Reported Outcome Measures are an important component of the evidence for health technology appraisal. Their incorporation into cost effectiveness analyses (CEA) requires conversion of descriptive information into utilities. This can be done using bespoke utility algorithms....

The arrival of personalized medicine in the clinic means that treatment decisions will increasingly rely on test results. The challenge of limited health care resources means that the dissemination of these technologies will be dependent on their value in relation to their cost; i.e. their cost...

The increasingly explicit use of health technology assessment continues to generate substantial public and academic policy debates. The debates are about puzzling issues whose correct resolution is not immediately obvious and the very explicitness of HTA’s use pinpoints the issues and locates...